Orasis Pharmaceuticals
Orasis Pharmaceuticals is a clinical-stage ophthalmic drug developer focused on presbyopia treatments, with 66 employees and $126M in total funding including a Series D in October 2024.
The growth story
Orasis Pharmaceuticals grew from 24 to 66 employees between 2022 and 2026, raising $126M along the way, most recently a Series D in October 2024.
About
Orasis develops pharmaceutical treatments for eye conditions, initially targeting presbyopia (age-related near vision loss). Its drugs aim to improve near vision without compromising distance vision, serving both patients and eye care professionals.
The company has raised $126M from investors including Johnson & Johnson Innovation and Arboretum Ventures, with its latest Series D closed in October 2024. With 66 employees, it operates in the competitive ophthalmic pharmaceuticals space against larger players.
Founders and leadership
Sales is the largest department with 20 employees, suggesting commercial preparation for potential drug approvals. Leadership likely combines ophthalmology expertise with pharmaceutical commercialization experience given the investor mix.
The Orasis Pharmaceuticals org chart
Elad Kedar (CEO) leads 39 mapped leaders with 2 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Sales 25 (-47% YoY), Business Development 11 (0% YoY), Entrepreneurship 9 (0% YoY), Healthcare Services 3 (-25% YoY), Marketing 3 (0% YoY), Operations 3 (0% YoY).
Talent flow
The team draws heavily from major eye care companies like Alcon (11 hires) and Novartis (6), with optometry schools like Wharton and New England College of Optometry feeding talent. Alumni move to smaller pharma firms like Dompé and Glaukos.
Most common previous employers of Orasis Pharmaceuticals staff: Alcon (11), ScoutPro Osmolarity System (6), Novartis (6), Bausch + Lomb (5), Teva Pharmaceuticals (4), RVL Pharmaceuticals (3). Former Orasis Pharmaceuticals employees most often moved to Dompé (3), Glaukos (2), LENZ Therapeutics (2), ANI Pharmaceuticals (2), UroGen Pharma (2), Tarsus Pharmaceuticals (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Orasis Pharmaceuticals: Leadership (30), Medical Devices (27), Pharmaceutical Sales (26), Management (23), Sales (23), Product Launch (22), Strategic Planning (22), Pharmaceutics (21).
Where the team actually sits
Orasis Pharmaceuticals people are concentrated in Israel (5), California, United States (5), United States (3), Texas, United States (3).
Frequently asked
Orasis Pharmaceuticals has 66 employees as of September 2026.
Orasis Pharmaceuticals has raised $126M in total, most recently a Series D round in October 2024.
Elad Kedar (CEO) sits at the top of Orasis Pharmaceuticals's reporting structure, with 2 direct reports.
The most common previous employers of current Orasis Pharmaceuticals staff are Alcon (11 people), ScoutPro Osmolarity System (6 people), Novartis (6 people).
Former Orasis Pharmaceuticals employees most often move to Dompé (3), Glaukos (2), LENZ Therapeutics (2).
The most common skills among Orasis Pharmaceuticals staff are Leadership, Medical Devices, Pharmaceutical Sales, Management, Sales.
Orasis Pharmaceuticals staff are concentrated in Israel (5), California, United States (5), United States (3).
Orasis Pharmaceuticals has about 25 people in Sales, down 47% over the past year, as of September 2026.
Orasis Pharmaceuticals has about 11 people in Business Development, up 0% over the past year, as of September 2026.
Computed from 46 current and 40 former Orasis Pharmaceuticals profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.